Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
New NCCN guidelines explain how to recognize and manage immunotherapy-related toxicities.
Similar to CAR-T cells, CAR-NK cells are reprogrammed with artificial receptors to recognize and attack cancer.
The first clinical trial will test a therapy designed to target a protein on cancer cells in young people with acute myeloid leukemia.
Our spring issue is devoted to the theme of treatment.
Customized treatments demonstrate good response rates for mantle cell lymphoma and chronic lymphocytic leukemia.
Some helpful websites to to look up if you or one of your loved ones is living with cancer.
Denise Delatorre became one of the first people in the country to receive the cutting-edge cancer treatment called CAR-T therapy.
$3.3 million Cancer Moonshot grant to study how immunotherapy impacts patients’ ability to fight off bugs
A month after receiving the treatment, there were higher levels of CAR T cells in the blood of patients who got the new therapy.
Genetically modified natural killer cells led to remission in eight out of eleven patients with lymphoma or leukemia.
Edited T cells survive and thrive in three patients in the first U.S. trial using this approach.
With new molecular “handles” and stimulating signals, metallic thin films become a stronghold for cancer-killing immune cells.
First-of-its-kind study offers early indication of factors linked to increased odds of success for patients out of options.
The $4M ‘Breakthrough’ award funds collaborative research aimed at destroying dormant disseminated tumor cells.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.